8-cyclohexyl-7H-purin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-cyclohexyl-7H-purin-2-amine
• 化学式: C₁₁H₁₅N₅
• 分子量: 217.27
• InChiKey: MXYFHQXWEISORZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL USE OF 2-(4-MORPHOLINOANILINE)-6-CYCLOHEXYL AMINOPURINE AND PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF
  申请人：Li Jiahao

  公开号：US20140086984A1

  公开（公告）日：2014-03-27

  The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also discloses is a method for preparing drugs for treating or preventing infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and protecting and improving the liver function, in which the compound is used alone or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome.
• PHARMACEUTICAL USE OF 2-(4-MORPHOLINOANILINE)-6-CYCLOHEXYL AMINOPURINE AND/OR SALT THEREOF FOR IMPROVING LIVER FUNCTIONING
  申请人：ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.

  公开号：US20150224106A1

  公开（公告）日：2015-08-13

  A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also disclosed is a method for preparing drugs for treating infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and improving t liver functioning, in which the compound and/or salt thereof is used optionally or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome.
• US9023385B2
  申请人：——

  公开号：US9023385B2

  公开（公告）日：2015-05-05